Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Structure of Cannabinoid Receptor Elucidated In New Study



According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

Share this!

October 24, 2016 | by Sarah Hand, M.Sc.

While researchers have long known that one of the active component in cannabis – known as tetrahydrocannabinol (THC) – acts on the cannabinoid receptors in the brain, the mechanisms behind this interaction were previously unknown. Now, researchers have uncovered the structure of the cannabinoid receptor 1 (CB1), in a study which was published in the journal Cell.

Using this crystal structure, the researchers were able to create a 3-D model of the CB1 receptor. According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

“With marijuana becoming more popular with legislation in the United States, we need to understand how molecules like THC and the synthetic cannabinoids interact with the receptor,” said co-author Raymond Stevens, a professor of Biological Science and Chemistry at the University of Southern California, “especially since we're starting to see people show up in emergency rooms when they use synthetic cannabinoids.”

According to the researchers, it’s unknown why THC derived from Cannabis sativa has such a high safety margin, compared to synthetic cannabinoids which can cause serious side effects in certain doses. Their research on the structure of CB1 could help drugmakers design safer therapeutics capable of acting on the receptor.

By synthesizing a synthetic cannabinoid known as AM6538, Stevens and his team were able to determine the conformation of the CB1 receptor. When studying the 3-D model of the CB1 receptor, the researchers identified multiple regions which may explain how THC and synthetic cannabinoids produce psychoactive effects on the body.

“Researchers are fascinated by how you can make changes in THC or synthetic cannabinoids and have such different effects,” said Stevens. “Now that we finally have the structure of CB1, we can start to understand how these changes to the drug structure can affect the receptor.”

Keywords: Cannabis, Drug Development, Drug Receptor


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.